Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated Biologics platform, Co. is developing therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals in the tumor microenvironment. Co.'s product candidates: SNS-101, which is Co.'s monoclonal antibody targeting the immune checkpoint V-domain Ig suppressor of T-cell activation; SNS-102, which is Co.'s monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4; and SNS-103, which is Co.'s monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1. The SNSE average annual return since 2021 is shown above.
The Average Annual Return on the SNSE average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SNSE average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SNSE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|